Israeli cancer therapy co Alpha Tau raises $26m
Alpha DaRT’s alpha-emitting atoms diffuse only a short distance, mainly affecting the tumor, and sparing the healthy tissue around it.
The company is now conducting clinical trials in multiple clinical indications across the world, including its first US trial at Memorial Sloan Kettering Cancer Center in New York, a pancreatic cancer trial at CHUM in Montreal, and trials at three academic institutions in Japan. Alpha Tau is also establishing global manufacturing facilities in Israel and elsewhere, and is in the process of obtaining the EU CE mark for marketing in Europe.
Alpha Tau CEO Uzi Sofer said, “We are humbled by the groundswell of continued support we’ve seen from both existing and new investors. This will enable us to push forward our mission to help cancer patients across the world, even during these challenging times in which Covid-19 is the focus of everyone’s health concerns.”
Alpha DaRT (Diffusing Alpha-emitters Radiation Therapy) enables highly potent and conformal alpha-irradiation of solid tumors. The treatment is delivered by intra-tumor insertion of radium-224 impregnated seeds. When the radium decays, its short-lived offspring is released from the seed, and disperses while emitting high-energy alpha particles that destroy the tumor. Since the alpha-emitting atoms diffuse only a short distance, Alpha DaRT mainly affects the tumor, sparing the healthy tissue around it.
Published by Globes, Israel business news – en.globes.co.il – on June 4, 2020
© Copyright of Globes Publisher Itonut (1983) Ltd. 2020